September 29, 2021 -- MeMed has developed a rapid test that can predict with greater accuracy than other tests if a COVID-19 patient's condition will deteriorate, according to a September 29 poster presentation at the 2021 American Association for Clinical Chemistry (AACC) annual meeting.
The test can give a response in 15 minutes and help signal if a patient may need lifesaving treatment. It measures the inflammatory biomarkers C-reactive protein, TNF-related apoptosis-inducing ligand, and interferon gamma-induced protein 10, and uses these values to calculate a COVID-19 severity score based on a scale of 0 to 100, with 100 indicating the highest likelihood of a severe outcome.
To develop the test, MeMed researchers first used a rapid point-of-care instrument that the company previously built to measure the biomarkers in 518 COVID-19 patients, 113 of whom had a severe outcome. Next, they created a model using a machine-learning algorithm that serves as the basis for the COVID-19 severity score.
The researchers, led by Dr. Niv Mastboim and Eran Eden, PhD, co-founder and CEO of MeMed, reported that the severity score has an area under the curve (AUC) of 0.86, outperforming other COVID-19 severity stratification tests in terms of accuracy, including the commonly used biomarker interleukin-6, which has an AUC of 0.77.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current